Dr. Herbert Yu

Co-founder/Chief Medical Officer

Dr. Herbert Yu is a co-founder of Anpac as served as chief medical officer since the company’s inception in 2010.

  • Dr. Yu has served as a professor and program director of cancer epidemiology at the University of Hawaii Cancer Center and an adjunct professor at Yale School of Public Health since 2012. He was a faculty member, from assistant professor to professor, at Yale University, School of Medicine from 2001 to 2011.
  • Being trained in medicine, epidemiology and clinical biochemistry, Dr. Yu conducts various laboratory-based clinical and epidemiologic investigations and has extensive experience in cancer research. He has designed and been involved in many clinical research projects that assess the molecular and genetic features of tumor specimens in relation to cancer characteristics and survival outcomes of patients with various kinds of cancers.
  • As a principal investigator and co-investigator, Dr. Yu has developed and participated in several large population-based epidemiologic studies that investigate gene-environment interactions in breast, endometrial, liver and pancreatic cancers.
  • Biomarkers under his investigation include genetic polymorphisms in DNA repair genes, DNA methylation and methylator phenotype in tumor suppressor genes and detoxification genes, protein markers, peptide growth factors and various non-coding transcripts.
  • Dr. Yu received his bachelor’s degree in medicine from Shanghai First Medical College in 1983. He also received a master of science degree in epidemiology and a PhD in clinical biochemistry from University of Toronto in 1990 and 1996, respectively.

Our world class leaders started with a question, “What if we could detect cancer before tumors start?”

Our Leadership Team

Over 200 patent applications filed globally with 107 patent applications issued.*

Our patented Cancer Differentiation Analysis (CDA) technology reinvents cancer screening and early detection with a “Blood Biopsy” that has no side effects in patients.

*As of September 30, 2019

“game changing”

CDA technology is called “game-changing” in Nobel Prize Laureate Summit on Biomedical Science (NPLS) publications.

Read the full article
©2019 Anpac Bio-Medical Science Co., Ltd.
;